Rate Control in Atrial Fibrillation

Tehran University of Medical Sciences

Status and phase: Completed; Phase 4

Conditions: Rapid Ventricular Response Atrial Fibrillation

Treatments: Drug: Verapamil; Drug: Diltiazem; Drug: Propranolol; Drug: Metoprolol

Study type: Interventional

Funder types: Other

Identifiers

NCT01655303

16057

Details and patient eligibility

About

Rate control in atrial fibrillation is a usual battle in emergency departments. Oral medications have a natural superiority to intravenous ones because they are easy-to-use and decrease the workload in busy emergency departments.

This study wants to find an effective oral medication for rate control in rapid ventricular response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are compared in patients with a stable hemodynamic status.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age more than 18 years old
• Stability in hemodynamic

Exclusion criteria

• Systolic blood pressure less than 90 mm Hg
• Altered mental status attributable to rapid ventricular response atrial fibrillation
• Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation
• Chest pain attributable to rapid ventricular response atrial fibrillation
• Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem
• History of asthma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

90 participants in 4 patient groups

Metoprolol Per Oral

Experimental group

Description:

50 mg Metoprolol

Treatment:

Drug: Metoprolol

Verapamil

Experimental group

Description:

40 mg Verapamil Per Oral

Treatment:

Drug: Verapamil

Propranolol

Experimental group

Description:

40 mg Propranolol Per Oral

Treatment:

Drug: Propranolol

Diltiazem

Experimental group

Description:

60 mg Diltiazem Per Oral

Treatment:

Drug: Diltiazem